By Craig Townsend, Director of Healthcare at 42T
As we approach the end of H1 2022, I have been thinking more about the COVID-19 pandemic and how it fundamentally changed the economics of healthcare. A lot of people were predicting that the pandemic would lead to a new wave of investment into healthcare and pandemic prevention which led me to write this month’s article. Spoiler alert, investment has dropped back to the pre pandemic baseline, and it turns out the predictions were wrong!
What can we do as healthcare and life science professionals to get more people interested in the medtech space, outside of a global pandemic?
As we learn to live alongside the SARS-CoV-2 Virus, things are returning to ‘normal’ and although there is a significant backlog in health systems around the world, what initiatives is the global healthcare sector focusing on in H1 2022?
Position: Director of Healthcare
Joined the team in: July 2021
Specialism/skills: Craig joined us from the world of Venture Capital and is our expert in investment, economics and start-up.
Fun fact: Has over 2,000 film reviews on IMDB!
This article will give you some good advice on who the regulators are, what differs region to region and some considerations when planning your own regulatory strategy.
Getting pre-compliance testing wrong can result in increased project costs and timescales, mismanaged expectations, and target markets not being achievable.
Director of Healthcare
Share this newsletter: